Jeffrey W. Albers Sells 11,033 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 11,033 shares of the firm’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $1,000,582.77. Following the sale, the director now directly owns 165,017 shares in the company, valued at $14,965,391.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Blueprint Medicines Stock Up 5.7 %

Shares of NASDAQ:BPMC opened at $94.79 on Thursday. Blueprint Medicines Co. has a 1 year low of $41.54 and a 1 year high of $101.00. The business has a 50 day simple moving average of $86.06 and a two-hundred day simple moving average of $72.75. The firm has a market capitalization of $5.80 billion, a PE ratio of -11.34 and a beta of 0.63. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The business had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. During the same quarter in the previous year, the business earned ($2.65) earnings per share. The company’s revenue for the quarter was up 85.5% compared to the same quarter last year. On average, equities analysts predict that Blueprint Medicines Co. will post -5.42 EPS for the current year.

Wall Street Analyst Weigh In

BPMC has been the topic of several research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 target price on shares of Blueprint Medicines in a report on Monday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 target price on shares of Blueprint Medicines in a report on Monday, December 11th. JMP Securities reaffirmed a “market outperform” rating and issued a $114.00 target price on shares of Blueprint Medicines in a report on Friday, February 16th. Citigroup lifted their target price on Blueprint Medicines from $54.00 to $65.00 and gave the stock a “sell” rating in a report on Friday, February 16th. Finally, Stifel Nicolaus lifted their target price on Blueprint Medicines from $95.00 to $97.00 and gave the stock a “buy” rating in a report on Tuesday, January 9th. Four research analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Blueprint Medicines currently has an average rating of “Hold” and an average target price of $85.43.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Pinebridge Investments L.P. purchased a new stake in shares of Blueprint Medicines in the second quarter valued at approximately $46,000. Compass Wealth Management LLC purchased a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $69,000. PNC Financial Services Group Inc. boosted its holdings in shares of Blueprint Medicines by 63.4% in the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 329 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Blueprint Medicines by 28.4% in the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 193 shares during the period. Finally, Cutler Group LLC CA boosted its holdings in shares of Blueprint Medicines by 1,685.7% in the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 944 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.